We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Politics > Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans
Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans
Politics

Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans

Last updated: March 16, 2022 5:00 am
Editorial Board Published March 16, 2022
Share
SHARE
15dc pfizer 1 facebookJumbo

But since Israel only recently began its second booster program, researchers could not determine whether the added protection was short-lived. Israel began offering fourth doses to health care workers in late December, then quickly broadened eligibility to those 60 and older and other vulnerable groups.

Updated 

March 15, 2022, 9:06 p.m. ET

The second study, of Israeli health care workers, showed that even though fourth shots of either Pfizer’s or Moderna’s vaccine boosted antibody levels, they were not very effective at preventing infections. Researchers said those findings underscored the urgency of developing vaccines that target whatever variant is circulating.

The National Institutes of Health in the United States and various vaccine manufacturers have been studying how the vaccines could be updated. One federal health official said results were not expected until the summer.

Some senior administration officials say that depending on the evidence, a second booster could make sense now for older Americans, but not for the general population. The F.D.A. is expected to convene a meeting of its expert advisory committee next month to discuss the issue of fourth shots. Developments on Pfizer’s request were reported earlier by The Washington Post.

Asked last month whether everyone would need another injection, Dr. Peter Marks, the F.D.A.’s top vaccine regulator, said, “Barring any surprises from new variants, maybe the best thing is to think about our booster strategy in conjunction with the influenza vaccine next fall, and get as many people as possible boosted then.” Dr. Anthony S. Fauci, the chief medical adviser to the White House, has suggested that any move toward a second booster now would most likely be aimed at those most at risk, possibly based on age and underlying conditions.

To date, about two-thirds of Americans 5 and older have been fully vaccinated with two shots of a vaccine. Only about half of those eligible for boosters have received them, but the proportion rises to two-thirds for those 65 and older, according to the Centers for Disease Control and Prevention.

In a call with reporters on Tuesday, senior administration officials said the administration was running short on funds for new doses. The administration has enough supply to manage a fourth shot for people 65 and older, one said, but could not expand that effort to everyone without more funding from Congress.

You Might Also Like

Joe Biden recognized with ‘aggressive’ prostate most cancers

Cuomo vows to eliminate unpopular Tier 6 pension coverage he enacted as NY governor

Mayor Adams contemplating pulling metropolis contracts for organizations the town deems antisemitic

US declare of state secrets and techniques privilege in Kilmar Abrego Garcia case is ‘inadequate,’ decide says

Youngsters die as USAID support cuts snap a lifeline for the world’s most malnourished

TAGGED:BioNTech SECenters for Disease Control and PreventionCoronavirus (2019-nCoV)ElderlyFood and Drug AdministrationNational Institutes of HealthPfizer IncResearchThe Washington MailVaccination and Immunization
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
A YouTuber’s Plane Crash Draws Doubts From Aviation Experts
Trending

A YouTuber’s Plane Crash Draws Doubts From Aviation Experts

Editorial Board January 23, 2022
3 Types of Baby Formula Recalled After Reported Bacterial Infections
Facing Subpoenas, Trump Allies Try to Run Out the Clock on Democrats
SoftBank’s Woes Are Mounting
Tim Ryan Struggles to Reach Ohio’s Exhausted Majority

You Might Also Like

Trump’s ‘One Big Beautiful’ finances invoice falls quick in key vote
Politics

Trump’s ‘One Big Beautiful’ finances invoice falls quick in key vote

May 16, 2025
Trump administration should resume  billion in funding for public well being departments, choose guidelines
Politics

Trump administration should resume $11 billion in funding for public well being departments, choose guidelines

May 16, 2025
Trump accuses ex-FBI head James Comey of assassination risk with ‘8647’ submit
Politics

Trump accuses ex-FBI head James Comey of assassination risk with ‘8647’ submit

May 16, 2025
Zohran Mamdani pledges to slash small charges and fines in half for small companies
Politics

Zohran Mamdani pledges to slash small charges and fines in half for small companies

May 16, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?